Skip to main content
. 2022 Jun 14;11(12):e025236. doi: 10.1161/JAHA.121.025236

Figure 6. Cost‐effectiveness acceptability curves.

Figure 6

Results from the probabilistic sensitivity analysis indicating the probability of the pooled cohort equation (PCE)+polygenic risk score for coronary artery disease (CAD‐PRS) being cost‐effective at different willingness‐to‐pay (WTP) thresholds. Compared with PCE alone, PCE+CAD‐PRS is likely to be cost‐effective with a probability of 94% and 99% at $50 000 WTP threshold and 98% and 99% at $100 000 WTP threshold in 5‐ and 10‐year time horizons, respectively.